Testing effectiveness (Phase 2)Study completedNCT01167166
What this trial is testing
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Who this might be right for
Acute Myelocytic LeukemiaAcute Lymphocytic LeukemiaMyeloproliferative Disease+1 more
Traws Pharma, Inc. 30